Catalio Capital Management LP Has $26.93 Million Holdings in Dianthus Therapeutics, Inc. $DNTH

Catalio Capital Management LP lowered its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 2.1% in the 4th quarter, Holdings Channel reports. The firm owned 653,572 shares of the company’s stock after selling 14,043 shares during the quarter. Dianthus Therapeutics accounts for approximately 5.0% of Catalio Capital Management LP’s portfolio, making the stock its 5th biggest position. Catalio Capital Management LP’s holdings in Dianthus Therapeutics were worth $26,934,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the fourth quarter worth about $40,000. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter worth about $27,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the third quarter worth about $64,000. Royal Bank of Canada lifted its stake in Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after purchasing an additional 542 shares during the last quarter. Finally, Quarry LP bought a new stake in Dianthus Therapeutics in the fourth quarter worth about $99,000. Institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on DNTH shares. Wedbush raised their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Robert W. Baird raised their price objective on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Stock Up 3.8%

Shares of DNTH stock opened at $81.89 on Thursday. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of -19.83 and a beta of 1.18. The company’s 50 day moving average is $86.81 and its 200 day moving average is $66.00. Dianthus Therapeutics, Inc. has a 52-week low of $16.64 and a 52-week high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. The trade was a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 149,121 shares of company stock worth $12,635,454. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.